Advertisement

Topics

Latest "Targeted Oncology" News Stories

08:08 EST 16th February 2019 | BioPortfolio

Here are the most relevant search results for "Targeted Oncology" found in our extensive news archives from over 250 global news sources.

More Information about Targeted Oncology on BioPortfolio

In addition to our news stories we have dozens of PubMed Articles about Targeted Oncology for you to read. Along with our medical data and news we also list Targeted Oncology Clinical Trials, which are updated daily. BioPortfolio also has a large database of Targeted Oncology Companies for you to search.

Showing "Targeted Oncology" News Articles 1–25 of 6,700+

Saturday 16th February 2019

Do Nutraceuticals Help Bipolar Depression?

Not according to this randomized, controlled study, which showed no benefit with N-acetylcysteine alone or combined with a mix of other mitochondrial-targeted supplements


Suzhou's CStone Pharma Schedules $304 Million Hong Kong IPO for Next Week

CStone Pharma, a Suzhou oncology company, plans to raise $304 million in its Hong Kong IPO at a valuation of $1.5 billion. Even though CStone is just two and one-half years-old, it has 14 oncology programs underway, including nine in clinical or IND stages. CStone plans to file a China NDA on its lead candidate, a PD-L1 immunotherapy, later this year. CStone has reduced the IPO price 23% from the ...

Friday 15th February 2019

Avapritinib receives Phase III clinical trial approval for GIST in China

SUZHOU, China, Feb. 15, 2019 /PRNewswire/ -- CStone Pharmaceuticals ("CStone") today announced that the National Medical Products Administration (NMPA) recently approved a Phase III clinical trial in China for its partnered drug candidate avapritinib as a third-line treatment against KIT-driven gastrointestinal stromal tumors (GIST). The study will be part of the global VOYAGER Phase II...


New Therapy for Aggressive Blood Cancer Discovered

NewsAcute myeloid leukemia is the most common form of acute leukemia.Contributed Author: 

H-RT should be the standard of care for men with low risk prostate cancer, study shows

Results from the NRG Oncology clinical study NRG-RTOG 0415 determined that a hypofractionated radiotherapy schedule, a treatment schedule that delivers a total dose of radiotherapy over a shorter period of time, is not worse than the conventional radiotherapy schedule in terms of bowel, bladder, sexual, and general quality of life as well as anxiety and depression for men with low risk prostate ca...

Stealth Bio’s IPO Raises $78M for Clinical Tests of Mitochondrial Drugs

Stealth BioTherapeutics has popped up on the radar with a $78 million IPO to fund clinical trials for drugs treating rare mitochondrial disorders. Shares of Stealth Bio (NASDAQ: MITO) made their stock market debut Friday at $12 apiece, which was the low end of the company’s targeted $12 to $14 range. The biotech sold 6.5 […]

Cambrooke Therapeutics and Trovita Health Science Announce Strategic Alliance for ENU® Nutrition

Cambrooke Therapeutics, a member of The Ajinomoto Group, and Trovita Health Science, a specialty medical nutrition company, announce a joint marketing

Bayer Snaps Up Rights to Two Cancer Drugs from Lilly’s $8B Loxo Deal

Bayer has just reclaimed some rights to two drugs from Loxo Oncology, which means it’s going to take more work for Loxo’s buyer, Eli Lilly, to justify the $8 billion it is paying for the company. Lilly (NYSE: LLY) this morning closed its buyout of Loxo, a developer of cancer drugs that target specific genetic […]

.@Roche's Perjeta secures NICE approval in adjuvant HER2+ metastatic #BreastCancer http://bit.ly/2GrhuD1  #pharma #cancer #oncology

. @Roche's Perjeta secures NICE approval in adjuvant HER2+ metastatic #BreastCancer http://bit.ly/2GrhuD1  #pharma #cancer

On #InternationalChildhoodCancerDay can I strongly recommend that you read @scchak's feature following a family trying to bring genetically-targeted cancer treatments to kids? https://rdcu.be/bmXzX pic.twitter.com/3IuzpO4ir2

On #InternationalChildhoodCancerDay can I strongly recommend that you read @scchak's feature following a family trying to bring genetically-targeted cancer treatments to kids? https://rdcu.be/bmXzX  pic.twitter.com/3IuzpO4ir2

Bayer Acquires Full Rights to Loxo Oncology’s Vitrakvi and LOXO-195

WHIPPANY, N.J., Feb. 15, 2019 /PRNewswire/ — Bayer has exercised its option, under a change-in-control clause in the collaboration agreement with Loxo Oncology, to obtain the exclusive licensing rights for the global development and commercialization, for Vitrakvi® (larotrectinib) and BAY 2731954 (LOXO-195). Both compounds are being developed globally for the treatment of adu...

Bayer acquires full rights to Vitrakvi, LOXO-195 from Eli Lilly's Loxo Oncology https://firstwordpharma.com/node/1625421?tsid=33 …

Bayer acquires full rights to Vitrakvi, LOXO-195 from Eli Lilly's Loxo Oncology https://firstwordpharma.com/node/1625421?tsid=33 …

Bayer kann Krebshoffnungsträger Larotrectinib nun alleine vermarkten

Der Pharma- und Agrarchemiekonzern Bayer hat die Übernahme seines Forschungspartners Loxo Oncology durch den US-Pharmakonzern Eli Lilly genutzt, um sich die vollen Rechte an zwei Krebshoffnungsträ...

Rainier Therapeutics Presents Data on Vofatamab in Patients with Advanced Urothelial Cell Carcinoma (Bladder Cancer) Previously Treated with Chemotherapy at ASCO GU 2019

– Preliminary data from FIERCE-21 Phase 2 trial highlighted in oral presentation supports advancement to pivotal study – – Single agent activity and long-term treatment duration demonstrated – Rainier Therapeutics, Inc., a privately-held clinical stage drug development company, today announced the presentation of preliminary data from ...

HOOKIPA Appoints Michael A. Kelly as Independent Director

HOOKIPA Pharma Inc. (“HOOKIPA”), a company developing a new class of immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform, today announced the appointment of Michael A. Kelly to the Company’s Board of Directors. Mr. Kelly is a former senior executive of Amgen, Inc. currently acting as Foun...

Abundant T Cell Clones in Smokers Tied to Crohn's Recurrence

(MedPage Today) -- Smokers with T cell-driven pathogenesis may benefit from targeted therapy

Global Anti-PD-(L)1 4Q18 sales: $MRK Keytruda $2151M (+66% YoY) $BMY Opdivo $1804M (+33%) Ono Opdivo $235M (+3%) $AZN Imfinzi $262M $RHHBY Tecentriq $248M (+89%) $REGN Libtayo $15M $PFE Bavencio N/A Total class at ~$19B run rate, that's >15% of global dr

Global Anti-PD-(L)1 4Q18 sales: $MRK Keytruda $2151M (+66% YoY) $BMY Opdivo $1804M (+33%) Ono Opdivo $235M (+3%) $AZN Imfinzi $262M $RHHBY Tecentriq $248M (+89%) $REGN Libtayo $15M

Proud to share our latest #oncology news in #kidneycancer. More data to be presented at @ASCO #GU19: http://bit.ly/2BGosA9  $MRKpic.twitter.com/ZE1PFH4qZs

Proud to share our latest #oncology news in #kidneycancer. More data to be presented at @ASCO #GU19: http://bit.ly/2BGosA9  $MRK pic.twitter.com/ZE1PFH4qZs

@Genentech did you know we have a triple Cytokine immune therapy in development? One includes IL-15. #CallMeLetsTalk Genentech to Develop Xencor IL-15 Cytokines in Immuno-Oncology Partnership https://www.genengnews.com/news/genentech-to-develop-xencor-il

@Genentech did you know we have a triple Cytokine immune therapy in development? One includes IL-15. #CallMeLetsTalk Genentech to Develop Xencor IL-15 Cytokines in Immuno-Oncology Partnership https://www.genengnews.com/news/genentech-to-develop-xencor-il-15-cytokines-in-immuno-oncology-partnership/ … via

University of Minnesota to offer new targeted therapy for recurrent brain tumors

GammaTile Therapy is an FDA-cleared, surgically targeted radiation therapy (STaRT) that is designed to delay tumor regrowth for patients with brain tumors. The first patient was treated by The post University of Minnesota to offer new targeted therapy for recurrent brain tumors appeared first on Compelo Medical Devices.

More cancer patients are living longer, studies show. But few are getting the help they need to stay healthy https://www.usatoday.com/in-depth/news/50-states/2019/02/13/life-after-cancer-survivors-oncology-survivorship-plans-long-term-health/2794121002/ 

More cancer patients are living longer, studies show. But few are getting the help they need to stay healthy https://www.usatoday.com/in-depth/news/50-states/2019/02/13/life-after-cancer-survivors-oncology-survivorship-plans-long-term-health/2794121002/ …

FDA Grants Priority Review to Merck’s Supplemental Biologics License Application for KEYTRUDA® (pembrolizumab) in Combination with Inlyta® (axitinib) as First-Line Treatment for Advanced Renal Cell Carcinoma

Application Based on Overall Survival and Progression-Free Survival Data from Phase 3 KEYNOTE-426 Trial Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has accepted and granted priority review for a new supplemental Biologics License Application (sBLA) for KEYTRUDA, M...

Brain Mets: Choosing and Sequencing Local vs Systemic Therapies

Dr Mark Kris discusses the importance of multimodality decision-making in the treatment of brain metastasis. Medscape Oncology

Bayer exercised option to obtain full licensing rights for larotrectinib and BAY 2731954 (LOXO-195)

Bayer has exercised its option, under a change-in-control clause in the collaboration agreement with Loxo Oncology, to obtain the exclusive licensing rights for the global development and commercialization, including the U.S., for larotrectinib (VITRAKVI®) and BAY 2731954 (LOXO-195). Both compounds are being developed globally for the treatment of adult and pediatric patients with advanced solid ...

As Lilly deal closes, Bayer secures full rights to Loxo's Vitrakvi

With the targeted cancer drug now exclusively held by Bayer, Lilly's buyout of Loxo becomes an $8 billion bet on the promise of the biotech's RET inhibitor.


Advertisement
Quick Search
Advertisement
Advertisement

 

News Quicklinks